Free tool
FAERS Monitor: Altreno
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209353 or its brand name (Altreno, Tretinoin). Reports on generic versions are filed under their own applications.
Reports
6,579
Serious
4,119
63% of reports
Hospitalization
1,417
Death reported
851
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use877
- drug ineffective731
- product use in unapproved indication493
- pain490
- vomiting450
- paraesthesia373
- abdominal pain upper368
- rash362
- nausea351
- diarrhoea347
- maternal exposure during pregnancy338
- headache335
- taste disorder332
- drug intolerance327
- gastrooesophageal reflux disease327
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 31 |
| 2006 | 24 |
| 2007 | 39 |
| 2008 | 114 |
| 2009 | 72 |
| 2010 | 78 |
| 2011 | 89 |
| 2012 | 153 |
| 2013 | 100 |
| 2014 | 147 |
| 2015 | 223 |
| 2016 | 342 |
| 2017 | 343 |
| 2018 | 461 |
| 2019 | 356 |
| 2020 | 381 |
| 2021 | 434 |
| 2022 | 514 |
| 2023 | 572 |
| 2024 | 684 |
| 2025 | 819 |
| 2026 | 566 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,580 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| taste disorderSignal | 332 | 53.2 | 47.8 | 16,682 |
| gastrooesophageal reflux diseaseSignal | 327 | 13.0 | 11.7 | 3,621 |
| maternal exposure during pregnancySignal | 338 | 12.2 | 11.0 | 3,454 |
| drug intoleranceSignal | 327 | 10.9 | 9.8 | 2,919 |
| paraesthesiaSignal | 373 | 7.6 | 6.9 | 2,141 |
| product use in unapproved indicationSignal | 493 | 6.4 | 5.9 | 2,249 |
| abdominal pain upperSignal | 368 | 5.7 | 5.2 | 1,441 |
| off label useSignal | 877 | 3.2 | 3.0 | 1,384 |
| vomitingSignal | 450 | 3.1 | 2.8 | 636 |
| rashSignal | 362 | 2.7 | 2.4 | 380 |
| painSignal | 490 | 2.6 | 2.3 | 474 |
| drug ineffective | 731 | 1.8 | 1.7 | 262 |
| diarrhoea | 347 | 1.7 | 1.6 | 107 |
| headache | 335 | 1.7 | 1.5 | 101 |
| nausea | 351 | 1.4 | 1.3 | 44 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.